These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6114104)

  • 1. Gas--liquid chromatographic determination of pipotiazine in plasma of psychiatric patients.
    Cooper SF; Lapierre YD
    J Chromatogr; 1981 Feb; 222(2):291-6. PubMed ID: 6114104
    [No Abstract]   [Full Text] [Related]  

  • 2. High-performance liquid chromatographic determination of pipotiazine in human plasma and urine.
    le Roux Y; Gaillot J; Bieder A
    J Chromatogr; 1982 Jul; 230(2):401-8. PubMed ID: 6125523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients.
    Chouinard G; Annable L; Kropsky M
    J Clin Pharmacol; 1978; 18(2-3):148-54. PubMed ID: 24061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled clinical evaluation of depot neuroleptics. A double-blind trial with pipotiazine undecylenate and fluphenazine enanthate.
    Ahlfors UG
    Acta Psychiatr Scand Suppl; 1973; 241():95-9. PubMed ID: 4147516
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].
    Woggon B; Dick P; Fleischhauer HJ; Gmür M; Gruber G; Angst J; Heimann H
    Int Pharmacopsychiatry; 1977; 12(4):193-209. PubMed ID: 22515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
    Jain RC; Ananth JV; Lehmann HE; Ban TA
    Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
    [No Abstract]   [Full Text] [Related]  

  • 7. How schizophrenic patients change during 3 years' treatment with depot neuroleptics.
    Dencker SJ; Frankenberg K; Lepp M; Lindberg D; Malm U
    Acta Psychiatr Scand; 1978 Feb; 57(2):115-23. PubMed ID: 24982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pipotiazine palmitate: a new depot neuroleptic.
    Simpson GM; Varga V
    Curr Ther Res Clin Exp; 1975 Mar; 17(3):276-80. PubMed ID: 236151
    [No Abstract]   [Full Text] [Related]  

  • 9. The strategy and value of neuroleptic drug monitoring.
    Curry SH
    J Clin Psychopharmacol; 1985 Oct; 5(5):263-71. PubMed ID: 2864358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentrations of antipsychotic drugs in psychiatric inpatients.
    Tokunaga H; Kudo K; Imamura T; Jitsufuchi N; Ohtsuka Y; Ikeda N
    Nihon Hoigaku Zasshi; 1997 Dec; 51(6):417-22. PubMed ID: 9545754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dynamics of the serum pipothiazine level in patients with schizophrenia during long-term treatment with this neuroleptic agent].
    Lipska B; Szukalski B; Nurowska K; Welbel L
    Psychiatr Pol; 1987; 21(1):14-9. PubMed ID: 2887001
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK; Wong KE; Tay WK; Gill RC
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients.
    Bechelli LP; Ruffino-Netto A; Hetem G
    Braz J Med Biol Res; 1983 Dec; 16(4):305-11. PubMed ID: 6143579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot pipotiazine 1970-1982: a review.
    Burch EA; Ayd FJ
    J Clin Psychiatry; 1983 Jul; 44(7):242-7. PubMed ID: 6134718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Initial results of a pharmacokinetic study of pipothiazine and its palmitic ester (Piportil L4) in a schizophrenic population].
    Girard M; Granier F; Schmitt L; Cotonat J; Escande M; Blanc M
    Encephale; 1984; 10(4):171-6. PubMed ID: 6149927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study.
    Jakovljevic M; Pivac N; Mihaljevic-Peles A; Mustapic M; Relja M; Ljubicic D; Marcinko D; Muck-Seler D
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):399-402. PubMed ID: 17126974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA; Milanes F; Starkey T; Slater V; Dominguez F
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract]   [Full Text] [Related]  

  • 19. AMDP psychopathology factors in chronic schizophrenia: a clinical trial of two long-acting neuroleptics.
    Lapierre YD; von Frenckell R
    Mod Probl Pharmacopsychiatry; 1983; 20():193-203. PubMed ID: 6137766
    [No Abstract]   [Full Text] [Related]  

  • 20. [Oxyprothepin decanoate in maintenance therapy of schizophrenia--a double-blind, standardized controlled study].
    Filip V; Faltus F; Hanáková S; Janecková E; Raboch J; Dobiásová A; Karen P; Posmurová M
    Cesk Psychiatr; 1985 Feb; 81(1):6-14. PubMed ID: 2858269
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.